Tesmilifene
Title: Tesmilifene
CAS Registry Number: 98774-23-3
CAS Name: N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine
Additional Names: DPPE
Molecular Formula: C19H25NO
Molecular Weight: 283.41
Percent Composition: C 80.52%, H 8.89%, N 4.94%, O 5.65%
Literature References: Intracellular histamine antagonist with chemopotentiating and cytoprotective activity. Structurally similar to tamoxifen, q.v., although binds anti-estrogen binding site (AEBS) with no affinity for the estrogen receptor. Prepn: L. J. Brandes, M. W. Hermonat, Biochem. Biophys. Res. Commun. 123, 724 (1984); and use as antineoplastic: eidem, US 4803227 (1989 to Univ. Manitoba); and study of binding affinity: M. Poirot et al., Bioorg. Med. Chem. 8, 2007 (2000). Spectral analysis of interaction with P450 isozymes: L. J. Brandes et al., Cancer Chemother. Pharmacol. 45, 298 (2000). Clinical evaluation in combination with cyclophosphamide in prostate cancer: L. J. Brandes et al., J. Clin. Oncol. 13, 1398 (1995); in combination with doxorubicin in breast cancer: L. Reyno et al., J. Clin. Oncol. 22, 269 (2004).
 
Derivative Type: Hydrochloride
CAS Registry Number: 92981-78-7
Manufacturers' Codes: BMS-217380-01; BMY-33419
Molecular Formula: C19H25NO.HCl
Molecular Weight: 319.87
Percent Composition: C 71.34%, H 8.19%, N 4.38%, O 5.00%, Cl 11.08%
Properties: White crystals from isopropanol + acetone (3:1), mp 156-158°. pKa 10.9.
Melting point: mp 156-158°
pKa: pKa 10.9
 
Therap-Cat: Antineoplastic adjunct (chemosensitizer).
Keywords: Antineoplastic Adjunct; Chemosensitizer.

Others monographs:
BudralazineSulfazametUreaseEtodroxizine
EucatropineAcetyltannic Acidtert-Amyl Methyl EtherTriadimenol
IndolmycinMercurous ChlorateSulfametroleAmmonium Nitrate
VasicineSarsaparillaNADPVanillic Acid
©2016 DrugLead US FDA&EMEA